Credit should go to SI’s good eye.
The focus of the Texas Heart Institute Regenerative Medicine Research Dept is, among other things, the “identifying mechanisms of heart failure with preserved ejection fraction”. Looking at the same in patients with reduced ejection refraction is therefore complementary.
https://www.texasheart.org/research/regenerative-medicine-research/our-department/
Also interesting to note that the Institute’s separate Stem Cell Center runs a number of trials on medical devices.
https://www.texasheart.org/research/stem-cell-center/
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-519
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |